Who are Fexuprazan Hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tegoprazan 50 mg, Vonoprazan Tablets, Tegoprazan 50 mg, tablets, orally, qd, Linaprazan glurate - Low dose, Vonoprazan, Amoxicillin and Levofloxacin, Vonoprazan, Amoxicillin, Levofloxacin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fexuprazan-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fexuprazan Hydrochloride — Competitive Intelligence Brief

Fexuprazan Hydrochloride (Fexuprazan Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-competitive acid blocker (P-CAB). Area: Gastroenterology.

marketed Potassium-competitive acid blocker (P-CAB) H+/K+-ATPase (proton pump) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Fexuprazan Hydrochloride (Fexuprazan Hydrochloride) — Daewoong Pharmaceutical Co. LTD.. Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fexuprazan Hydrochloride TARGET	Fexuprazan Hydrochloride	Daewoong Pharmaceutical Co. LTD.	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (proton pump)
Tegoprazan 50 mg	Tegoprazan 50 mg	First People's Hospital of Hangzhou	marketed	Potassium-Competitive Acid Blocker (P-CAB)	H+/K+-ATPase
Vonoprazan Tablets	Vonoprazan Tablets	Humanis Saglık Anonim Sirketi	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (proton pump)
Tegoprazan 50 mg, tablets, orally, qd	Tegoprazan 50 mg, tablets, orally, qd	Zhang Xiaofeng,MD	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase
Linaprazan glurate - Low dose	Linaprazan glurate - Low dose	Cinclus Pharma Holding AB	phase 3	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (gastric proton pump)
Vonoprazan, Amoxicillin and Levofloxacin	Vonoprazan, Amoxicillin and Levofloxacin	Ain Shams University	phase 3	Potassium-competitive acid blocker (P-CAB)	H+/K+ ATPase
Vonoprazan, Amoxicillin, Levofloxacin	Vonoprazan, Amoxicillin, Levofloxacin	Aga Khan University	phase 3	Potassium-competitive acid blocker (P-CAB)	H+/K+ ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-competitive acid blocker (P-CAB) class)

Cinclus Pharma Holding AB · 2 drugs in this class
Aga Khan University · 1 drug in this class
Ain Shams University · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Humanis Saglık Anonim Sirketi · 1 drug in this class
Zhang Xiaofeng,MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fexuprazan Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/fexuprazan-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab